Literature DB >> 11804649

Mouse models of Huntington's disease.

Liliana B Menalled1, Marie-Françoise Chesselet.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder. In 1993 the mutation that causes HD was identified as an unstable expansion of CAG repeats in the IT15 gene. Since then one of the most important advances in HD research has been the generation of various mouse models that enable the exploration of early pathological, molecular and cellular abnormalities produced by the mutation. In addition, these models have made it possible to test different pharmacological approaches to delay the onset or slow the progression of HD. In this article, insights gained from mouse models towards the understanding of HD and the design of new therapeutic strategies are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11804649     DOI: 10.1016/s0165-6147(00)01884-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  90 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

Review 2.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 3.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

4.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

5.  Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

Authors:  Danielle A Simmons; Rishi A Mehta; Julie C Lauterborn; Christine M Gall; Gary Lynch
Journal:  Neurobiol Dis       Date:  2010-10-23       Impact factor: 5.996

Review 6.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

Review 7.  Neurogenesis and exercise: past and future directions.

Authors:  Henriette van Praag
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

8.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

9.  AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Authors:  Nicholas R Franich; Helen L Fitzsimons; Dahna M Fong; Matthias Klugmann; Matthew J During; Deborah Young
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

10.  Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Authors:  Liliana B Menalled; Jessica D Sison; Ying Wu; Melisa Olivieri; Xiao-Jiang Li; He Li; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.